Global Albumin Market Report to 2030

company logo

Albumin market

Albumin market

Albumin market

Dublin, 25 July 2022 (GLOBE NEWSWIRE) — The report “Albumin Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2021–2030” has been added to from ResearchAndMarkets.com offer.

According to Verified Market Research, Albumin Market was valued at USD 4,813.5 Million in 2020 and is projected to reach USD 8,956.07 Million by 2030, growing at a CAGR of 6.4% from 2021 to 2030.

Serum albumin is the most abundant plasma protein, constituting about 50% of human plasma proteins. Albumin is obtained from a plasma fractionation process where human serum albumin and bovine serum albumin are most widely used. Recombinant albumin is produced using recombinant techniques in rice plants, yeast species, and other cell lines. Albumin is used as a blood volumizer and is used in the treatment of various diseases including surgical blood loss, shock, burns, trauma, chronic liver disease, hypovolemia, hemorrhage, acute liver failure, hypoalbuminemia and acute respiratory distress syndrome.

The increase in the prevalence of rare diseases, shock, trauma, burns and other fatalities is the major factor contributing to the growth of the albumin market. Additionally, other factors fueling the market growth include increasing adoption of albumin products, rising awareness of recombinant albumin products and increasing non-therapeutic application albumin as an excipient and drug formulator.

Additionally, many companies are increasing their presence in the market, thereby expanding their business into new markets. For example, in June 2020, Biotest took a major step in its international expansion strategy by recording the first sales of human albumin in China, which is used to stabilize blood circulation in diseases such as chronic kidney disease. and liver and burns. These aforementioned factors have led to increase the growth of the albumin market.

Additionally, owing to high demand for albumin in R&D activities and increasing production of immunoglobulins, the increase in non-therapeutic applications of albumin has led to drive the growth of the market. According to the National Clinical Trials Registry, approximately 294 ongoing clinical trials are related to albumin through different phases of development for different indications. Additionally, in March 2020, Curium received FDA approval for the Pulmotech MAA Kit for the preparation of Technetium Tc 99m Albumin Aggregate Injection. It is a single photon emitting agent for lung imaging as an adjunct to lung perfusion assessment. Thus, advancements in the development of albumin products are expected to drive the market growth.

Conversely, development of cost-effective therapies through large-scale production and high market potential in untapped emerging economies is expected to provide lucrative growth opportunities for the market and is expected to hamper the growth of the market. Nowadays, people are more aware of their health, which compels them to maintain their health and increase the demand for albumin for drug development. This has encouraged many key players to enter the emerging markets, thereby providing a lucrative growth opportunity in the albumin market.

The global albumin market is segmented on the basis of type, use, material, end-user, and region. By type, the market is categorized into human serum albumin, bovine serum albumin, and recombinant albumin.

According to the application, it is fragmented into therapeutics, drug and vaccine formulation, medium component and other applications. Regionally, it is analyzed across North America, Europe, Asia-Pacific and LAMEA.

Some of the major companies operating in the global albumin market are Baxter International Inc., China Biologic Products, Inc, CSL Limited, Grifols, SA, Merck KGaA, Novozymes, Octapharma AG, Takeda Pharmaceuticals Inc, Thermo Fisher Scientific, and Ventria Bioscience. .

Main benefits for stakeholders

  • This report provides an in-depth analysis of current and emerging market trends and dynamics in the global albumin market to identify prevailing opportunities

  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies

  • Comprehensive analysis of factors driving and restraining market growth is provided

  • Region and country analysis is provided to understand market trends and dynamics

Main topics covered:

Chapter 1 Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview
3.1. Market definition and scope
3.2. Main findings
3.2.1. Best Investment Pockets
3.3. Market share analysis, 2016
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the prevalence of rare diseases and various life-threatening conditions
3.4.1.2. Increased albumin demand
3.4.1.3. Growing preferences for recombinant albumin
3.4.1.4. Increased non-therapeutic application of albumin
3.4.2. Constraints
3.4.2.1. Strict government regulations
3.4.2.2. Risks associated with albumin
3.4.3. Opportunities
3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of cost-effective therapeutics through large-scale production
3.4.4. Impact analyzes
3.5. Government regulations
3.6. Patent analysis (2013-2018)
3.6.1. Patent analysis, by year
3.6.2. Analysis of patents for the year 2017, by country

Chapter 4: Albumin Market, By Product
4.1. Insight
4.1.1. Market size and forecast
4.2. Human serum albumin
4.2.1. Key Market Trends, Growth Drivers and Opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Bovine serum albumin
4.3.1. Key Market Trends, Growth Drivers and Opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Recombinant albumin
4.4.1. Key Market Trends, Growth Drivers and Opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

Chapter 5: Albumin Market, By Application
5.1. Insight
5.1.1. Market Size and Forecast (Value)
5.2. Therapeutic
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Formulation of drugs and vaccines
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Media component
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Other Apps
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

Chapter 6: Albumin Market, By Region

Chapter 7: Company Profiles
7.1. Baxter International Inc.
7.1.1. Company presentation
7.1.2. Company overview
7.1.3. Operating business areas
7.1.4. Product portfolio
7.1.5. Company performance
7.2. China Biologic Products Holdings, Inc.
7.2.1. Company presentation
7.2.2. Company overview
7.2.3. Operating business areas
7.2.4. Product portfolio
7.2.5. Company performance
7.3. Csl Limited
7.3.1. Company presentation
7.3.2. Company overview
7.3.3. Operating business areas
7.3.4. Product portfolio
7.3.5. Company performance
7.4. Grifols SA (Grifols International, SA)
7.4.1. Company presentation
7.4.2. Company overview
7.4.3. Operating business areas
7.4.4. Product portfolio
7.4.5. Company performance
7.4.6. Key strategic moves and developments
7.5. Merck Kgaa
7.5.1. Company presentation
7.5.2. Company overview
7.5.3. Operating business areas
7.5.4. Product portfolio
7.5.5. Company performance
7.6. Novozymes A/S (Albumedix Ltd.)
7.6.1. Company presentation
7.6.2. Operating business areas
7.6.3. Product portfolio
7.6.4. Company performance
7.7. Octapharma S.A.
7.7.1. Company presentation
7.7.2. Company overview
7.7.3. Operating business areas
7.7.4. Product portfolio
7.7.5. Company performance
7.8. Takeda Pharmaceuticals
7.8.1. Company presentation
7.8.2. Company overview
7.8.3. Operating business areas
7.8.4. Product portfolio
7.8.5. Company performance
7.9. Thermo Fisher Scientific Inc (Affymetrix, Inc.)
7.9.1. Company presentation
7.9.2. Company overview
7.9.3. Operating business areas
7.9.4. Product portfolio
7.9.5. Company performance
7.10. Ventria Biosciences
7.10.1. Company presentation
7.10.2. Company overview
7.10.3. Categories of operating products
7.10.4. Product portfolio

For more information about this report visit https://www.researchandmarkets.com/r/8nfneo

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Comment

Your email address will not be published.

beautiful home decor Williams vs Radokano match postponed Brian Kelly, LSU player Myles Brennan, retires from football Black Adam and Stripe are seemingly heading to MultiVersus Bryce Dallas Howard claims she received payment.
beautiful home decor Williams vs Radokano match postponed Brian Kelly, LSU player Myles Brennan, retires from football Black Adam and Stripe are seemingly heading to MultiVersus Bryce Dallas Howard claims she received payment.